Evidence map›Paper›PMID 25702360›Full record

ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2014

Long-term efficacy and toxicity of cholinesterase inhibitors in the treatment of Alzheimer disease.

David B Hogan

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Recent progress of nanomedicine in the treatment of Alzheimer's disease.Frontiers in cell and developmental biology · 2023
    Review
  12. Review
  13. Article
  14. Neuregulins in Neurodegenerative Diseases.Frontiers in aging neuroscience · 2021
    Article
  15. Review
  16. Neuroactive venom compounds obtained fromThe journal of venomous animals and toxins including tropical diseases · 2021
    Article
  17. Article
  18. Review
  19. Article
  20. Evidence-based complementary and alternative medicine : eCAM · 2020
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

David B Hogan

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Though the symptoms of Alzheimer disease go on for years, the phase 3 trials of the cholinesterase inhibitors (ChEIs), the current mainstay of symptomatic pharmacotherapy for this condition, were typically of only 3- to 6-months' duration. We have limited data on long-term (that is, a year or more) therapy with these agents. In this review, we explore the available information on the biological and clinical effects of long-term ChEI therapy, what happens when these agents are discontinued, and examine what others have recommended An individualized approach to deciding on whether to carry on with a ChEI should be taken. If continued, treatment goals should be clarified and patients monitored over time, for both drug-related benefits and adverse effects.

Indexed as

Alzheimer DiseaseCholinesterase InhibitorsHumansCholinesterase Inhibitors

Identifiers

PMID25702360
PMCPMC4304580

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.